contraindications of glp 1 agonist Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks The GLP-1 Agonists and Obesity:

To provide timely, complementary evidence, we conducted a comparison of tirzepatide and semaglutide in patients at low, moderate and high cardiovascular risk who were diagnosed with obesity and type 2 diabetes and subgroups with specific cardiovascular conditions

This rapid and significant decline in muscle mass while taking GLP- 1 RA places certain patient populations already predisposed to sarcopenia at higher risk for muscle loss and adverse events

Endocrinology 153: 3054-3065, 2012

Infusions with GIP(3-30)NH 2 in healthy individuals during a mixed meal test or an oral glucose tolerance test as well as in persons with obesity in the fasting state do not affect glucagon levels (87, 90)

That's when she noticed a lot of the people who were on ventilators or dying had something in common: obesity